Take a look at our latest updates across different markets regarding launches, alliances, participations, events, expert opinions and more.
Discover our participation in the event we joined alongside the Uruguayan Society of Medical and Pediatric Oncology.
We are expanding our portfolio with another product for breast cancer treatment.
Supporting Hospital Durand's inaugural Blue Run to fight prostate cancer.
Setting a new standard of care in advanced prostate cancer treatment.
Leading the pharmaceutical industry into the future.
24th Lymphoma, Leukemia, and Myeloma Congress: the ideal scenario to reaffirm our commitment.
We had the pleasure of attending the Hematology Update Conference on October 1st.
A record-breaking congress with the latest innovations.
A different approach to managing symptoms associated with uterine fibroids.
Connecting with the medical community at the 61st Argentine Congress of Urology, hosted by the SAU.
As part of the Interior Conferences organized by the Hematology Society.
We launched Ledaga®, the first gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma approved in Argentina.
Both the medical community and Varifarma have reason to celebrate! Our product has been added to two of the leading medical recommendation guidelines.
Another year of expanding our scientific expertise in this academic event.
At Varifarma, we had the opportunity to actively participate in the congress, where we attended scientific sessions, workshops, and meetings with leading experts in the field.
In Varifarma we continue to take part in scientific events to stay at the forefront of new healthcare innovations.
Find the latest news of this innovative test as a genomic tool to evaluate tumour behavior over the years for an accurate choice of treatment.
Present at the “Daily Hematology” Conference in Montevideo from April 24 to 26.
Our genomic test myChoice CDx Plus has been recognized by the ESGO-ESMO-ESP 2024 consensus with a Level of Evidence 1A.
Varifarma launched GORAX® (Relugolix) at the International Symposium “Advances in Urology 2024” organized by the Argentine Society of Urology.
We Launched Gorax (Relugolix) 120mg, the first LHRH antagonist with oral intake in Argentina.
Developed by Varifarma, Gorax is a revolutionary breakthrough in advanced prostate cancer treatment.
A new therapeutic alternative with multiple indications arrives to Varifarma!
We continue to increase our treatment options for our patients! We’re launching Tepadina 400mg.
Another year full of innovation, launches, and new options for patients. We celebrate a year of innovation and progress at Varifarma 2023: Launches that make a difference!
Within the framework of the congress, the 1st meeting of the Uruguayan Lymphoma Group (GULI) and the XVII Hemato-Oncological Nursing Workshops were held.
Varifarma was present at the recent course of the Peruvian Society of Hematology on Immunotherapy with Blinatumomab to explore pioneering advances in the treatment of Acute Lymphoblastic Leukemia (ALL). Dr. Laura García from Mexico gave a presentation highlighting the fundamental role of this innovative therapy and the importance of accurate patient profiling.
SUEM Workshop on Pituitary Pathology: Cushing and Acromegaly in Uruguay, with the presence of VARIFARMA and participation of distinguished experts.